Thirty-three breast cancer patients underwent neoadjuvant chemotherapy, and therefore, were scanned for DW and DCE-MRI in the following three time-points: before NAT, after the first cycle of NAT, and after all NAT cycles. Here, BRD2 is linked to breast carcinoma.